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Abstract: Bacterial resistance to antibiotics has proven difficult to control over the past few decades.
The large group of multidrug-resistant bacteria includes carbapenemase-producing bacteria (CPB),
for which limited therapeutic options and infection control measures are available. Furthermore,
carbapenemases associate with high-risk clones that are defined by the sequence type (ST) to which
each bacterium belongs. The objectives of this cross-sectional and retrospective study were to
describe the CPB population isolated in a third-level hospital in Southern Spain between 2015 and
2020 and to establish the relationship between the ST and the epidemiological situation defined by
the hospital. CPB were microbiologically studied in all rectal and pharyngeal swabs and clinical
samples received between January 2015 and December 2020, characterizing isolates using MicroScan
and mass spectrometry. Carbapenemases were detected by PCR and Sanger sequencing, and STs
were assigned by multilocus sequence typing (MLST). Isolates were genetically related by pulsed-
field gel electrophoresis using Xbal, Spel, or Apal enzymes. The episodes in which each CPB was
isolated were recorded and classified as involved or non-involved in an outbreak. There were
320 episodes with CPB during the study period: 18 with K. pneumoniae, 14 with Klebisella oxytoca,
9 with Citrobacter freundii, 11 with Escherichia coli, 46 with Enterobacter cloacae, 70 with Acinetobacter
baumannii, and 52 with Pseudomonas aeruginosa. The carbapenemase groups detected were OXA, VIM,
KPC, and NDM with various subgroups. Synchronous relationships were notified between episodes
of K. pneumoniae and outbreaks for ST15, ST258, ST307, and ST45, but not for the other CPB. There
was a major increase in infections with CPB over the years, most notably during 2020, coinciding
with the COVID-19 pandemic. This study highlights the usefulness of gene sequencing techniques to
control the spread of these microorganisms, especially in healthcare centers. These techniques offer
faster results, and a reduction in their cost may make their real-time application more feasible. The
combination of epidemiological data with real-time molecular sequencing techniques can provide a
major advance in the transmission control of these CPB and in the management of infected patients.
Real-time sequencing is essential to increase precision and thereby control outbreaks and target
infection prevention measures in a more effective manner.
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1. Introduction
There has been an alarming rise in bacterial resistance to antibiotics over the past
two decades, representing a “silent pandemic” that appears unstoppable. This resistance
has become especially frequent in healthcare-related infections (HCRIs) worldwide [1–3].
However, there has also been an increase in the emergence and transmission of multidrug-
resistant bacteria in the community setting over the past few years, including residential
facilities and care homes. The more frequent hospitalization of these residents has favored
exchanges between hospital and community, increasing the capacity to spread resistant
bacteria in each setting [3]. The World Health Organization (WHO) has declared infection
by these microorganisms as an emerging disease that poses a major public health threat
worldwide [1–3].
The large group of carbapenem-resistant bacteria includes carbapenemase-producing
bacteria (CPB), for which there are limited therapeutic options, and infection control mea-
sures have proven ineffective to prevent the dissemination of these bacteria to date [4].
The WHO list of global priority pathogens includes carbapenem-resistant Acinetobacter
baumannii (CRAb) and Pseudomonas aeruginosa (CRPa) and carbapenem-producing Enter-
obacteriaceae (CPE) [2]. The most frequently observed carbapenem-resistance mechanism is
the production of carbapenemases [5]. Control of these infections is further hampered by
the horizontal transmission of these enzymes via plasmids among different Enterobacteri-
aceae [4].
In 2018, one-third of Acinetobacter spp. isolates obtained in the European Union (EU)
were resistant [6], and numerous outbreaks increased morbidity and mortality rates, mainly
in intensive care units (ICUs). A worldwide increase was observed in the frequency of
patients colonized or infected by CPE, which was above the EU mean in Spain [5]. The
European Center for Disease Control (ECDC) reported an increase in combined resistances
in Escherichia coli and Klebsiella pneumoniae over the past few years [3]. K. pneumoniae is
the most prevalent CPE [2] and responsible for the majority of outbreaks in healthcare
centers [7]. CPE infections were first detected in Spain in 2005, and their number had
multiplied 16-fold by 2019 [8].
In addition, carbapenemases are enzymes that associate with certain high-risk clones [8]
that are defined by the sequence type (ST) to which each bacterium belongs. The STs
most frequently associated with carbapenemases in K. pneumoniae are ST258, which is
predominant worldwide [8], and ST307, which is also associated with a higher mortality [9].
In Germany, it was reported that E. coli ST131 is a high-risk clone that should be monitored
very closely [10], alongside ST38, located in various European countries [10]. In Spain, the
STs most frequently associated with carbapenemases are ST11, 13, 15, 16, 101, 147, 340, 384,
388, 405, 437, 464, 512, 846 and 1235 [8].
Carbapenemases can be divided into metallocarbapenemases (zinc-dependent class
B) and non-metallocarbapenemases (zinc-independent classes A, C, and D) [11]. The first
carbapenemase detected was in class A K. pneumoniae [11], and some carbapenemases
appear more frequently than others. The first carbapenemase-producing isolates detected
in Spain belonged to the KPC group [8]. OXA-48 group carbapenemases are currently
the most abundant, mainly among Klebsiella spp. and Enterobacter spp. [5], and are the
most common resistance mechanism among CPEs in Spain [5]. Other carbapenemases
frequently reported in Spain are VIM-1, KPC-2, IMP, and NDM-1 [8].
Since 2020, a rise in CPB resistance in our setting coincided with the COVID-19
pandemic, which has been accompanied by populations at risk of severe complications
and long-term sequelae and by longer hospital stays and the prescription of an elevated
amount of antibiotics. These factors have led to an elevated risk of nosocomial CBP in-
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fections, as recently reported [12–14]. In addition, COVID-19 was especially prevalent in
our hospital catchment area from 2020, and the patients frequently required hospitaliza-
tion, as recorded by the Andalusian Health Service (https://www.juntadeandalucia.es/





cessed on 1 July 2021).
The objectives of this study were to describe the CPB population isolated in a third-
level hospital between 2015 and 2020 and to establish the relationship between STs and the
epidemiological situation as defined by the hospital.
2. Material and Methods
This retrospective cross-sectional study included adult patients admitted to the De-
partments of Internal Medicine and its Specialties, ICUs (general and cardiac), and the
Department of General Surgery and its Specialties of the Virgen de las Nieves University
Hospital in Granada (Spain). This hospital provides specialized care to a population of
around 331,220 inhabitants. No exclusion criteria were applied, except for repeat microbio-
logical studies of the same episode. For the colonization study, the presence of CPB was
studied in rectal (RS) and pharyngeal (PS) swabs received by the Clinical Microbiology
Laboratory between 1 January 2015 and 31 December 2020 (5415 RS and 1034 PS for 3107
episodes studied before 2020 and 2308 during 2020). For the study of “possible infection
episodes”, clinical samples from different localizations were studied by applying standard
clinical microbiology procedures, detecting CPB as previously described [15]. In brief,
samples were seeded on selective culture medium CHROMID® ESBL (BioMérieux, Marcy-
l’Étoile, France) and incubated at 37 ◦C in aerobiosis for 48 h. Isolates were identified by
using the MicroScan system (Beckman Coulter, Brea, CA, USA) and mass spectrometry
(Maldi-Tof ®, Brucker Daltonik GmbH, Bremen, Germany). Resistance was characterized
with the MicroScan system, using currently available Neg Combo panels, and interpreted
according to the clinical cutoff points defined by the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) [16]. Carbapenemase was detected using the colorimetric
Neo-Rapid CARB Kit ® (Rosco Diagnostica A/S, Taastrup, Denmark) and immunochro-
matography (NG5-Test Carba, NG Biotech, Guipry-France to detect KPC, NDM, VIM, IMP,
and OXA-48-like enzymes, and K-Set, Coris BioConcept, Gembloux, Belgium to detect
OXA-23) in isolates meeting EUCAST cutoff point criteria for CPB screening. In parallel,
isolates identified in swab and clinical samples were sent to the reference laboratory for
molecular typing of nosocomial pathogens and genotypic detection of antimicrobial resis-
tance mechanisms of interest under the regional Integrated Program for the Prevention
and Control of Healthcare-related Infections and Appropriate Utilization of Antibiotics
(acronym in Spanish, PIRASOA) led by the Microbiology Department of Virgen Macarena
Hospital in Seville.
2.1. Microbiological Study of Carbapenemase-Producing Bacteria (CPB) under the
PIRASOA Program
The susceptibility to ertapenem, imipenem, and meropenem was investigated by
disk diffusion in Mueller Hinton agar, using EUCAST clinical cutoff points to inter-
pret the results [16]. Carbapenemase activity inhibition [17] was studied by disk dif-
fusion using meropenem, meropenem/boronic acid, meropenem/dipicolinic acid, and
meropenem/cloxacillin disks as well as a temocillin disk (Rosco Diagnostica, Taastrup,
Denmark). Carbapenemase and MLST genes were studied by PCR using specific primers
and Sanger sequencing until 2018 and subsequently massive sequencing (Illumina Inc.,
San Diego, CA, USA). Sequences were analyzed with CLC Genomics Workbench, v10
software (Qiagen Iberia, Las Rozas de Madrid, Madrid, Spain). Determinants of resis-
tance were detected using ResFinder (https://cge.cbs.dtu.dk/services/ResFinder) (ac-
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cessed on 1 July 2021). and CARD (https://card.mcmaster.ca/) (accessed on 1 July
2021). databases, and MLST was identified using the MLST finder 2.0 database (https:
//cge.cbs.dtu.dk/services/MLST) (accessed on 1 July 2021). Clonal relationships among
isolates were evaluated by pulsed-field gel electrophoresis (PFGE). Complete chromosomal
DNA digestion in agarose gel was performed with XbaI (Enterobacterales), SpeI (Pseu-
domonas spp. and Stenotrophomonas), and ApaI (Acinetobacter spp.) according to the species.
The resulting restriction fragments were separated in the CHIEF DR-II system (Bio-Rad
Laboratories, Alcobendas, Madrid, Spain) with 1% agarose gel. The gels were subsequently
stained with ethidium bromide, illuminated with ultraviolet light, and photographed in an
automatic Gel Logic 200 Imaging System (Kodak, Rochester, NY, USA).
The conversion, normalization, and analysis of band patterns were performed using
Bionumerics 7.6 software (AppliedMaths, Jollyville Rd., Austin, TX, USA), analyzing the
patterns as previously described. Band position tolerance and optimization were set at
1%. An unweighted pair group method with arithmetic mean (UPGMA) was employed
to generate a dendrogram and the Dice coefficient was used to measure genetic similarity
among isolates. PFGE patterns with ≥90.0% similarity were considered in the same group
as closely related isolates.
2.2. Epidemiological Study
Episodes in which each carbapenemase-producing microorganism was isolated were
recoded to avoid repetition with the same patient. An episode was defined as each hospital
stay in which one or several different carbapenemase-producing microorganisms were
isolated, only considering the first isolate of each microorganism during the hospital
stay for infection or colonization study. When there were multiple isolated of the same
microorganism during the same episode, one was selected according to the following
criteria and order:
1. Isolate described in a PIRASOA report;
2. Isolate corresponding to infection study;
3. Isolate not reported in infection study, corresponding to colonization study.
The PIRASOA program describes the ST of the microorganism and its genetic simi-
larity to other microorganisms of the same species from any hospital in Andalusia. It also
reports whether the relationship with other microorganisms was recent or derived from a
common transmission focus. It was determined whether a CPB had a synchronous (SR)
or asynchronous relationship (AR) with others of the same species when the following
criteria were met: (1) they belong to the same clone of an ST, (2) patients coincided in their
hospital stay, and/or (3) the genetic study indicates direct transmission among patients
and/or very recent exposure to a common reservoir. An SR was considered when the first
criterion and one other criterion were met and an AR when only one criterion was met.
It was also recorded whether the CPB was involved or not in an outbreak of HCRI,
defined by two or more cases of HCRI due to the same microorganism and associated in
space and time with suspicion of an epidemiological link. The emergence of a single case of
HCRI by a new, or unknown, or re-emergent infectious agent of mandatory declaration was
considered an outbreak of nosocomial infection, henceforth “nosocomial outbreak” [18].
2.3. Influence of COVID-19 Infection during 2020
Data were compared between 2019 and 2020 on tested patients with a positive result
for COVID-19 (n = 178 episodes), including their age, sex, length of hospital stay, and in-
hospital consumption of imipenem (IP), meropenem (MP), and/or piperacillin–tazobactam
(PTZ) as daily dose per 1000 stays (DDD/1000 stays).
2.4. Statistical Study
The involvement of episodes in which an SR was reported in a declared nosocomial
outbreak was examined by constructing contingency tables and applying Fisher’s exact
test. The comparison between sexes was analyzed in the same way. The comparison by age
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was studied with the Student’s t-test after establishing the normality of data distribution
with the Kolmogorov–Smirnov test. IBM SPSS Statistics v. 19 was used for data analyses.
p < 0.05 was considered significant.
3. Results
Between 1 January 2015 and 31 December 2020, 320 episodes of CPB were identified:
118 episodes of K. pneumoniae, 14 of Klebisella oxytoca, 9 of Citrobacter freundii, 11 of E. coli,
46 of Enterobacter cloacae, 70 of A. baumannii, and 52 of P. aeruginosa. Among these, 39
episodes were excluded because there was no definitive PIRASOA report and four be-
cause the clinical history of the patient was missing from the Andalusian Health Service
database. Among the 43 episodes (13.4%) lost to the study, 34.9% involved K. pneumoniae,
6.9% K. oxytoca, 4.6% C. freundii, 6.9% E. coli, 2.3% E. cloacae, 13.9% A. baumannii, and
30.2% P. aeruginosa. Out of the final sample of 277 episodes, 103 involved K. pneumoniae,
11 K. oxytoca, 7 C. freundii, 8 E. coli, 45 E. cloacae, 64 A. baumannii, and 39 P. aeruginosa.
3.1. Description of Episodes
The most frequently isolated CPB in the studied episodes was K. pneumoniae (37.19%
of total episodes), followed by A. baumannii (23.10%) and E. cloacae (16.25%) (Table 1).
K. pneumoniae was detected in more numerous episodes every year except for 2018, when
more episodes with P. aeruginosa were detected, and 2019, when there were more episodes
with A. baumannii. Over the six-year study period, episodes with CPB were most frequent
in 2020 (37.54%). There has been an increase in A. baumannii in episodes over the past
two years and an increase in E. cloacae over the past year. The number of episodes each
year rose from 6 in 2015 (2.17% of total episodes) to 123 in 2020 (37.54%). Globally, there
were 156 episodes of infection and 121 of colonization. However, as depicted in Table 1,
infection episodes were much more frequent than colonization episodes in 2016 and 2017,
there was a similar frequency of infection and colonization episodes in 2018 and 2019, and
colonization episodes (57) were much more frequent in 2020 (47).
The carbapenemase groups detected in this study were OXA, VIM, KPC, and NDM
with their subgroups (Table 2). Table 3 exhibits the relationships between ST and car-
bapenemase for each species. There were four peak episodes with K. pneumoniae of ST258,
ST307, ST15, and ST45, mainly associated with KPC-3, OXA-48, NDM-5, and OXA-48,
respectively. There were fewer episodes with K. oxytoca and C. freundii, and only four STs
were found in K. oxytoca, highlighting the association of ST36 with VIM-1, and six STs in
C. freundii, highlighting the production of OXA-48 in three of the STs. Table 3 highlights
the production of OXA-48 in E. coli with ST58, ST69, ST405, and ST648. However, the most
frequent carbapenemase in E. cloacae was VIM-1, closely related to ST78, with OXA-48
being the second most frequent. Notably, the production of OXA-23 was associated with
ST2 in A. baumannii. A wide variety of carbapenemases was detected in P. aeruginosa,
highlighting the relationship of IMP-8 with ST348, the most frequent ST. ST175 and ST253
were less frequently detected, mainly associated with OXA-50 and IMP-16, respectively.
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Table 1. Colonization/infection episodes of each carbapenemase-producing bacteria in each year.
Years/Episodes
Microorganisms 2015 2016 2017 2018 2019 2020 Total
Infection Colonization Infection Colonization Infection Colonization Infection Colonization Infection Colonization Infection Colonization Infection Colonization
K.
pneumoniae 1 3 16 5 10 2 6 2 12 5 21 20 66 37
K. oxytoca 0 0 3 0 2 0 2 2 0 1 0 0 7 4
C. freundii 0 0 0 0 0 0 0 0 0 2 2 3 2 5
E. coli 0 0 0 0 1 0 1 1 0 1 2 2 4 4
E. cloacae 0 2 4 0 3 1 6 2 4 2 12 9 29 16
A. baumannii 0 0 0 0 0 0 2 2 17 17 8 18 27 37
P. aeruginosa 0 0 0 0 7 0 6 6 6 7 2 5 21 18













Table 2. Subgroups of carbapenemases detected in each carbapenemase-producing bacteria (CPB).
Carbapenemase Types
OXA VIM IMP KPC NDM Total
Microorganisms OXA-1 OXA-23 OXA-48 OXA-50 OXA-58 OXA-244 OXA-245 VIM-1 VIM-2 VIM-63 IMP-8 IMP-16 IMP-23 KPC-2 KPC-3 NDM-5
K. pneumoniae 1 56 1 4 1 1 32 8 102
K. oxytoca 1 8 2 11
C. freundii * 4 2 1 1 2 10
E. coli 5 1 2 8
E. cloacae 16 28 1 45
A. baumannii 47 17 64
P. aeruginosa * 1 2 3 1 14 10 9 40




(6.07%) 1 (0.36%) 1 (0.36%)
46









* CPB in which more than one carbapenemase is detected in an episode.
Table 3. Description in the microorganisms of carbapenemase and sequence types.
SEQUENCIO-TYPES
CARBAPENEMASE TYPES










KPC-2 KPC-3 0XA-1 OXA-23 0XA-48 0XA-50 0XA-58 0XA-244 0XA-245 VIM-1 VIM-2 VIM-63 IMP-8 IMP-16 IMP-23 NDM-5 NotAvailable
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3.2. Description of the Association among ST, Type of Relationship, and Involvement in a
Nosocomial Outbreak of Infection with CPB
This association was more frequent in K. pneumoniae, E. cloacae, A. baumannii, and
P. aeruginosa (Table 4). In K. pneumoniae, SRs were only reported for ST15, ST258, ST307,
and ST45, the STs with episodes included in outbreaks. ARs alone were reported for the
other STs detected, none of which had more than three episodes. An association was found
between the presence of an SR in episodes and involvement in an outbreak (p = 0.000007299).
In E. cloacae, PIRASOA reported an SR in only two of the eight STs detected (ST114 and
ST78), but only ST114 was involved in an outbreak, and the association between the
presence of an SR and involvement in an outbreak was just short of statistical significance
(p = 0.06829). In A. baumannii, only two STs (ST1 and ST2) were found, being ST1 in all
episodes except for one; A. baumannii had an SR with others in half of the episodes and
an AR in the remaining half. No significant association was found (p = 1) between the
presence of an SR and involvement in an outbreak. Finally, in P. aeruginosa, six STS were
detected and four of these were SRs: ST175, ST253, ST348, and ST845, but only ST253 was
involved in an outbreak. No significant association was found (p = 1) between the presence
of an SR and involvement in an outbreak.









Sequence Type AR SR Total OB NO OB YES Total
ST1 1 0 1 1 0 1
ST11 2 0 2 2 0 2
ST128 1 0 1 1 0 1
ST147 1 0 1 1 0 1
ST15 4 8 12 6 6 12
ST1774 1 0 1 1 0 1
ST25 1 0 1 1 0 1
ST258 8 21 29 26 3 29
ST307 8 21 29 20 9 29
ST307/cgST3303 3 0 3 3 0 3
ST307/cgST5556 1 0 1 1 0 1
ST321 1 0 1 1 0 1
ST37 1 0 1 1 0 1
ST392 1 0 1 1 0 1
ST405/cgST5158 3 0 3 3 0 3
ST45 4 7 11 7 4 11
ST512 1 0 1 1 0 1
ST525 1 0 1 1 0 1
ST896 3 0 3 3 0 3






ST108 1 1 1 1
ST111 1 1 1 1
ST114 3 10 13 10 3 13
ST1262 1 1 1 1
ST24 1 1 1 1
ST50 2 2 2 2
ST78 13 9 22 22 22
ST90 4 4 4 4








ST1 1 0 1 1 0 1
ST2 31 32 63 45 18 63
Total 32 32 64 46 18 64








ST175 3 8 11 11 11
ST2242 1 1 1 1
ST253 4 6 10 4 6 10
ST277 1 1 1 1
ST348 1 13 14 14 14
ST845 1 1 2 2 2
Total 11 28 39 33 6 39
Type of relationship: synchronous (SR) or asynchronous relationship (AR). Outbreak: OB.
As shown in Table 5, episodes with SR did not correspond to episodes involved in an
outbreak, and episodes with AR were even involved in outbreaks in some cases.
Table 5. Comparison between identified SRs and those involved in a nosocomial outbreak of CPB.
CPBs SR OB YES AR OB YES
K. pneumoniae 57 21 46 1
K. oxytoca 4 0 7 0
C. freundii 2 0 5 0
E. cloacae 19 3 26 0
A. baumannii 32 12 32 6
P. aeruginosa 28 4 11 2
Type of relationship: synchronous (SR) or asynchronous relationship (AR). Outbreak: OB.
3.3. Influence of Infection with COVID-19 during 2020
The absolute number of CPB infections was higher during 2020 than during 2019,
attributable to a marked rise in the number of samples studied rather than a higher
percentage of positive results (4.5% in 2020 vs. 5.6% in 2019). Table 6 compares clinical
data of patients testing during 2019 (74) and 2020 (104), positive for COVID-19 infection,
including age (p = 0.014), sex (not significant), hospital stay, hospital occupation, and
prescriptions of PTZ, IMP, and PTZ (daily dose per 1000 stays).
Table 6. Clinical data for episodes of carbapenemase-producing bacteria.
Parameters 2019 2020
Age, years 63.36 57.48
Standard deviation 16.601 17.254
Males, % 65 60
Females, % 35 40
Hospital stay, days 7.75 8.79
Hospital occupation, % 77.56 77.24
Piperacillin–tazobactam * 65.13 66.88
Imipenem * 6.71 5.13
Meropenem * 47.45 61.21
* daily dose per 1000 stays (DDD/1000).
4. Discussion
This study describes carbapenemase-producing microorganisms isolated over the past
six years in the microbiological laboratory of a tertiary hospital in Southern Spain. The
main findings were an increasingly elevated transmission of these bacteria in both hospital
and community settings and a major rise in the detection of CPB.
The capacity to detect CPB and their resistances has significantly improved through
technological advances and the rigorous implementation of screening and control protocols.
However, the upsurge of CPB cases in 2020 can be attributed at least in part to the COVID-
19 pandemic, which led to a major rise in the number of studied episodes due to an increase
in hospital stays, among other reasons. The resulting overload of hospital departments
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hampered the application of infection prevention measures, and there was an increased
administration of antibiotics (often inappropriate) to prevent and treat bacterial over-
infection in patients with pneumonia [19]. The inappropriate use of antibiotics is one cause
of the increasingly frequent emergence of resistance to carbapenem, among other antibiotics.
However, improvements in the diagnostic capabilities of microbiology laboratories over
time should also be taken into account, which would also influence an increase in the
detection of infectious episodes.
Four groups of carbapenemases (OXA, VIM, KPC, and NDM) and corresponding
subgroups were detected, all previously reported in Spain. Some were found in more than
one microorganism species (OXA-48, IMP-8, VIM-1, VIM-63, and KPC-3) and the others
were detected in a single species. The most abundant subgroup was OXA-48 (in 29.79% of
episodes), which is also the most prevalent subgroup worldwide [5], followed by VIM-1
(17.12%), OXA-23 (16.44%), and KPC-3 (12.33%). The most frequently isolated bacteria in
these episodes was K. pneumoniae, one of the most widely disseminated CPB worldwide
and largely responsible for the alarm caused by CPB, given the limited therapeutic options
and high mortality rates [7].
The relationships between STs and carbapenemases were explored in the detected CPB,
followed by a search for ST–carbapenemase combinations that have been reported in Spain
for each CPB, highlighting isolates of: K. pneumoniae ST15-OXA-48 [20,21], ST258-KPC-
3 [8,22], ST307-OXA-48 [23,24], and ST512-KPC-3 [23,25–27]; K. oxytoca ST36-VIM 1 [28];
E. coli ST58-OXA-48 [29]; E. cloacae ST114-OXA-48 [30]; A. baumannii ST1-OXA-23 [31]; and
P. aeruginosa ST175-VIM-2 [32,33].
No other combinations were found, either because they were not previously detected in
a Spanish hospital or were detected but not published. CPB associated with STs or carbapen-
emases were found, but no relationship was observed between STs and carbapenemase.
Although not as notorious as K. pneumoniae, the other CPB described in this study
form part of a group of multidrug-resistant microorganisms that pose a major public health
threat [34] and show increased diversity over time, as reported in a Portuguese study [4].
The frequency of their detection is rising among colonized and infected hospital patients,
despite the implementation of infection prevention and control measures and routine colo-
nization screenings [4]. There is also a trend towards more frequent nosocomial outbreaks,
especially of K. pneumoniae [7], and towards their longer persistence as colonizers of hospi-
talized patients and in the hospital setting. This creates “silent” reservoirs and carriers of
CPB over prolonged time periods, hampering control of their dissemination [7,11]. The
comprehensive and exhaustive implementation of available control measures is essential.
In our setting, these include the surveillance and follow-up of HCRIs and nosocomial out-
breaks and active communication from the microbiology departments on microorganisms
of concern.
We highlight the importance of genetic sequencing techniques for controlling the
spread of these microorganisms, given the speed with which results are obtained. A re-
duction in their cost may allow their real-time performance to be more widely available
at health centers. Data obtained on the STs and carbapenemase subgroup of a CPB indi-
cate its pathogenicity, dissemination capacity, local prevalence, therapeutic options, and
responses to treatment and can also yield information on changes in the resistances of these
bacteria [4,7]. These techniques can be highly effective for the detection and control of noso-
comial outbreaks. When only the species and antibiogram of microorganisms are identified
but not their ST, it is not known whether multiple unrelated STs might be involved, and
this question would be resolved by real-time molecular analysis. Without this information,
an outbreak is declared when there appear to be two or more cases of hospital-acquired
infection. Accordingly, an outbreak is declared in the hospital when there are two or more
patients with the infection who shared hospital space and/or staff/equipment at some time
since their admission (epidemiological link). If cases continue to emerge among patients
successively admitted at different times to the same unit, the possibility of a common
reservoir is investigated to establish the epidemiological link, i.e., an SR. The association
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observed between the presence of an SR and involvement in outbreaks suggests that the
epidemiological criteria for declaring an outbreak were correct because relationships were
observed among microorganisms that were subsequently found to have the same lineage.
However, it cannot be assumed that CPB with identical STs are involved in the same chain
of transmission without considering the epidemiological evidence [35].
In conclusion, there has been a major increase in infections with CPB over the years,
especially during 2020, coinciding with the COVID-19 pandemic. The combination of
epidemiological data with real-time molecular sequencing data represents a major advance
in the control of CPB transmission and the management of infected patients. The increased
precision offered by molecular sequencing techniques and the possibility of their real-
time performance can contribute to a greater control of nosocomial outbreaks and a more
effective targeting of infection prevention measures.
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